IGFBP7 and acute kidney injury: Recently, a secondary analysis from the Sapphire study in adults demonstrated that [TIMP-2]•[IGFBP7] determined early in the setting of critical illness identified AKI patients at increased risk for mortality or requirement for renal replacement therapy (RRT) within 9 months following AKI [24].